共 50 条
- [21] Phase III double-blind trial of Arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancerJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (31) : 4967 - 4973Deshmane, VijayaLaxmiKrishnamurthy, S.Melemed, Allen S.Peterson, PatrickBuzdar, Aman U.
- [22] Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer (vol 28, pg 4594, 2010)JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : 2293 - 2293Di Leo, A.Jerusalem, G.Petruzelka, L.
- [23] Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trialLANCET ONCOLOGY, 2021, 22 (11): : 1530 - 1540Fennell, Dean A.Ewings, SeanOttensmeier, ChristianCalifano, RaffaeleHanna, Gerard G.Hill, KayleighDanson, SarahSteele, NicolaNye, MavisJohnson, LucyLord, JoanneMiddleton, CalleySzlosarek, PeterChan, SamGaba, AartiDarlison, LizWells-Jordan, PeterRichards, CathyPoile, CharlotteLester, Jason F.Griffiths, Gareth
- [24] Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trialLANCET ONCOLOGY, 2013, 14 (03): : 228 - 235Robertson, John F. R.Ferrero, Jean-MarcBourgeois, HuguesKennecke, Hagende Boer, Richard H.Jacot, WilliamMcGreivy, JesseSuzuki, SamuelZhu, MinMcCaffery, IanLoh, ElwynGansert, Jennifer L.Kaufman, Peter A.
- [25] Fulvestrant plus capivasertib versus placebo in metastatic ER positive breast cancer (FAKTION): a randomised, double-blind, placebo-controlled, phase II trialBREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 530 - 531Howell, Sacha JonCarucci, MargheritaCasbard, AngelaCox, CatrinButler, RachelAlchami, FouadBale, CatherineBezecny, PavelJoffe, JohnathanMoon, SarahTwelves, ChrisVenkitaraman, RamachadranWaters, SimonJones, Robert Hugh
- [26] Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mgCANCER RESEARCH, 2012, 72Di Leo, A.Jerusalem, G.Petruzelka, L.Torres, R.Bondarenko, I. N.Khasanov, R.Verhoeven, D.Pedrini, J. L.Smirnova, I.Lichinitser, M. R.Pendergrass, K.Garnett, S.Rukazenkov, Y.Martin, M.
- [27] Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trialLANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (04): : 318 - 326Knoll, Greg A.Fergusson, DeanChasse, MichaelHebert, PaulWells, GeorgeTibbles, Lee AnneTreleaven, DarinHolland, DavidWhite, ChristineMuirhead, NormanCantarovich, MarceloPaquet, MichelKiberd, BryceGoorishankar, SitaShapiro, JeanPrasad, RameshCole, EdwardPilmore, HelenCronin, ValerieHogan, DeboraRamsay, TimGill, John
- [28] Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trialLANCET ONCOLOGY, 2023, 24 (12): : 1334 - 1348Monk, Bradley J.Toita, TakafumiWu, XiaohuaLimon, Juan C. VazquezTarnawski, RafalMandai, MasakiShapira-Frommer, RonnieMahantshetty, UmeshEstevez-Diz, Maria del PilarZhou, QiLimaye, SewantiGodinez, Francisco J. RamirezKussler, Christina OppermannVarga, SzilviaValdiviezo, NataliaAoki, DaisukeLeiva, ManuelLee, Jung-YunSulay, RaymondKreynina, YuliaCheng, Wen-FangRey, FelipeRong, YiKe, GuihaoWildsmith, SophieLloyd, AndrewDry, HannahNunes, Ana TablanteMayadev, Jyoti
- [29] Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trialLANCET ONCOLOGY, 2015, 16 (07): : 839 - 847Kordes, SilPollak, Michael N.Zwinderman, Aeilko H.Mathot, Ron A.Weterman, Mariette J.Beeker, AartPunt, Cornelis J.Richel, Dick J.Wilmink, Johanna W.
- [30] Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST StudyJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4530 - 4535Robertson, John F. R.Llombart-Cussac, AntonioRolski, JanuszFeltl, DavidDewar, JohnMacpherson, EuanLindemann, JustinEllis, Matthew J.